The startup harnesses microfluidics and cellular platforms to map condensates in molecular detail.
US-based startup Transition Bio develops a proprietary drug discovery platform called Condensomics which leverages droplet microfluidics, cellular imaging, and machine learning. Its technology enables the study of biomolecular condensates, which are implicated in many diseases, with high precision. The startup harnesses microfluidics and cellular platforms to map condensates in molecular detail. Additionally, machine learning algorithms on proprietary datasets model spatiotemporal networks in cells for target discovery, validation, and drug design.